Health Condition 1: - Health Condition 2: G588- Other specified mononeuropathies
Conditions
Interventions
Intervention1: Group CP: Patients will receive the Capsule Pregabalin 75mg BID therapy along with Cognitive Behavioural Therapy (CBT) for 3 months
Control Intervention1: Group PR: Patients will receiv
Sponsors
University College of Medical Sciences Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Patients with established diagnosis of PHN with evident allodynia and hyperalgesia, Patients should have had pain for at least 3 months weeks after healing of rash, Patients with pain intensity =4/10 on (NRS-Pain Scale)
Exclusion criteria
Exclusion criteria: Patients with history of neurological interventions for PHN, Other source of acute or chronic pain confounding the diagnosis, Patients with recent history ofMI, DM, pancreatitis and vasculitis,Patients with recent history of surgery or intake of pregabalin in last 4 week, Patient with cognition impairment or alcohol/ psychotropic drugs abuse,Patients with a history of treatment with CBT
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients achieving NRS-Pain score =3/10Timepoint: Baseline, At the end of first week,2nd week,4th week, 6th week,8th week and 12th week. | — |
Secondary
| Measure | Time frame |
|---|---|
| BDI-II score and PCS scoreTimepoint: Baseline, At the end of first week,2nd week,4th week, 6th week,8th week and 12th week.;Comparison of mRNA expression of mTORC1 and IL-6Timepoint: Baseline and 12th week;The neuropathic component of pain using NPSI and PDQ scoresTimepoint: Baseline, At the end of first week,2nd week,4th week, 6th week,8th week and 12th week. | — |
Countries
India
Contacts
Public ContactGeetanjali Chilkoti
University College of Medical Sciences, Delhi
Outcome results
None listed